Jam

Quince Therapeutics announced a securities purchase agreement to raise approximately $11.5 million upfront, with the potential for an additional $10.4 million if warrants are exercised. The financing, priced at a premium, will fund working capital, R&D, and general corporate purposes, extending its operational runway into Q2 2026 (or potentially H2 2026). The placement is led by Nantahala Capital and is set to close in June 2025.

UBS Wealth Management US welcomes Mellany Bagtas as a Financial Advisor in New York City, based at the 299 Park Avenue office. Bagtas, previously at Morgan Stanley, brings experience to serve high-net-worth clients, offering tailored financial strategies. UBS highlights her expertise in wealth preservation, planning, and customized solutions.

Sunflower Bank has appointed Josh Wilson as Regional President for Arizona and New Mexico to drive growth in those markets. With $8.2 billion in assets, the bank aims to expand its commercial banking relationships, leveraging Wilson’s extensive experience in financial services, including leadership roles in private equity and regional banking. The bank offers a range of services and operates branches in Arizona and New Mexico, as well as national services across 43 states.

Altigen Technologies launched the next generation of its MaxCloud UC platform, a UCaaS solution, featuring enhanced resilience, usability, and expanded functionality. The upgrade includes a new Active/Active/Active architecture for reliability, browser-based clients, updated mobile apps, AI-driven transcription, CRM integration, and web conferencing improvements. The update delivers tangible advantages for Altigen’s channel partners and aims to streamline operations and improve user experience.

New Found Gold Corp. completed the second tranche of its “bought deal” offering, raising C$63.48 million. This final tranche, including the underwriters’ over-allotment option, generated C$21.4 million and involved Charity Flow-Through Common Shares and common shares. Funds will support exploration expenses at the Queensway Gold Project. Major shareholder Eric Sprott retained his stake. The offering, underwritten by firms including BMO, underscores strong investor confidence and is subject to regulatory approvals.

Garmin introduces the GPSMAP 15×3 chartplotter, featuring a 15-inch ultrawide touchscreen designed for an enhanced boating experience. The new display offers superior clarity and optimized helm space, providing the benefits of dual screens in a single unit. The GPSMAP 15×3 includes built-in sonar capabilities, preloaded mapping, and seamless connectivity for a streamlined and immersive experience.

MINISO Group (MNSO) successfully held its annual general meeting in Hong Kong on June 12, 2025, with shareholders approving all resolutions. This crucial event reaffirms MINISO’s commitment to strong corporate governance and shareholder engagement. The positive outcome boosts investor confidence in the company’s sustainable growth and its position in the global retail market.

NXP Semiconductors and Rimac Technology are collaborating to accelerate software-defined vehicle (SDV) architectures. Rimac will integrate NXP’s S32E2 processors into its next-gen ECU platform, consolidating functionalities and reducing ECUs. This enables improved safety, efficiency, and agile development for vehicle applications. The solution leverages the S32E2’s real-time processing capabilities, meeting the demands of modern SDVs, and includes comprehensive system support from NXP. Rimac will launch this platform via a hypercar program with expansion planned for other sectors.

Faraday Future will unveil its FX Super One, the first model for its FX brand, on June 29, 2025, in Los Angeles. The event targets stockholders, partners, and influencers aiming to redefine luxury mobility with an AI-powered, mass-market MPV. A public launch follows on July 17 with production slated by the end of 2025.

Insmed Incorporated announced a $750 million public offering of common stock, selling 7,812,500 shares at $96.00 each. Proceeds will fund brensocatib’s R&D, ARIKAYCE’s commercialization, and pipeline expansion. This strategic move aims to bolster financial standing and accelerate drug development across pulmonary and inflammatory conditions. The offering, led by major financial institutions, is expected to close on June 13, 2025, subject to customary conditions.